Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for negative symptoms and inflammatory biomarkers in schizophrenia and schizoaffective disorders
IRCT201310083210N5Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of memantine in schizophrenia and schizoaffective disorder, sponsored by Shahid Beheshti University of Medical Sciences. Started Jan 2015; status: completed.
02
Drugs
memantine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on IRCT201310083210N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201310083210N5.